In the April 2013 edition of The Journal of Thoracic and Cardiovascular Surgery we found “Hyperthermic intraoperative pleural cisplatin chemotherapy extends interval to recurrence and survival among low-risk patients with malignant pleural mesothelioma undergoing surgical macroscopic complete resection”.
The primary author of this relatively new mesothelioma medical journal article is David J. Sugarbaker, MD, of the Division of Thoracic Surgery at Brigham and Women’s Hospital, Harvard Medical School, in Boston.
This study, as seen below, shows the benefit of hyperthermic intraoperative cisplatin chemotherapy lavage in certain patients with malignant pleural mesothelioma.
From the Abstract for this 2013 mesothelioma treatment medical article:
Objective: Local recurrence limits long-term survival in patients with malignant pleural mesothelioma. We investigated whether hyperthermic intraoperative cisplatin chemotherapy lavage affects the interval to recurrence and overall survival among patients with favorable prognostic factors.
Methods: Using a preoperative risk assessment algorithm we had previously developed and validated, we retrospectively identified a cohort of patients treated with cytoreductive surgery from 2001 to 2009. The patients had epithelial histologic findings on biopsy and were characterized as having a low risk of early recurrence and death….
Results: The cohort criteria identified 103 patients: 72 who received hyperthermic intraoperative cisplatin chemotherapy and 31 who did not….
Conclusions: A favorable outcome and minimal incremental morbidity support the incorporation of hyperthermic intraoperative cisplatin chemotherapy into multimodality treatment strategies for patients with low-risk epithelial malignant pleural mesothelioma.
Be assured that when we learn of other possible medical advances as regards the treatment of mesothelioma, we will report them here on Asbestos HUB.
Asbestos-Mesothelioma Case Evaluation Form
Free. Confidential. No Obligation.